Labrucherie Gil M — SEC insider filings
SEC reporting owner CIK 1394875. 34 insider filings on record with FilingPulse; latest filed 2026-11-18.
Transaction summary — filings shown
Covers all 34 filings on record, filed 2020-08-19 to 2026-11-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 7 legs across 4 filings — 145,262 shares, $629,159 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 20 legs across 11 filings — 264,439 shares, $5,094,980 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 32.
- Largest priced transaction: sale of 50,000 shares @ $19.81 ($990,500) in NEKTAR THERAPEUTICS, filed 2021-02-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | SVP, COO & CFO | 15 | — | 17 legs · 244,439 sh · $4,262,621 | 15 |
| Septerna, Inc. (SEPN) | Chief Financial Officer | 6 | 5 legs · 40,000 sh · $229,164 | 3 legs · 20,000 sh · $832,359 | 3 |
| Rezolute, Inc. (RZLT) | Director | 8 | 2 legs · 105,262 sh · $399,996 | — | 9 |
| ACELYRIN, Inc. (SLRN) | CFO and CBO | 5 | — | — | 5 |
Insider filings — Labrucherie Gil M
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-18 | 4 | Septerna, Inc. (SEPN) | Sale (S): 15,815 @ $41.48 · Sale (S): 3,485 @ $41.99 · Sale (S): 700 @ $43 | EDGAR |
| 2026-02-10 | 4 | Septerna, Inc. (SEPN) | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-11-21 | 4 | Rezolute, Inc. (RZLT) | Grant/award (A): 21,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-08-11 | 4 | Septerna, Inc. (SEPN) | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Rezolute, Inc. (RZLT) | Grant/award (A): 9,000 @ $0 · Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | Septerna, Inc. (SEPN) | Purchase (P): 6,282 @ $5.59 · Purchase (P): 3,718 @ $5.85 | EDGAR |
| 2025-02-21 | 4 | Septerna, Inc. (SEPN) | Purchase (P): 10,500 @ $5.51 · Purchase (P): 14,500 @ $5.88 · Purchase (P): 5,000 @ $5.85 | EDGAR |
| 2025-02-20 | 4 | Rezolute, Inc. (RZLT) | Grant/award (A): 25,500 @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-02-07 | 4 | Septerna, Inc. (SEPN) | Grant/award (A): 222,000 (derivative) @ $0 | EDGAR |
| 2024-09-04 | 4 | ACELYRIN, Inc. (SLRN) | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | ACELYRIN, Inc. (SLRN) | Grant/award (A): 184,042 (derivative) @ $0 | EDGAR |
| 2024-01-25 | 4 | Rezolute, Inc. (RZLT) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-01-11 | 4 | ACELYRIN, Inc. (SLRN) | Grant/award (A): 855,513 (derivative) @ $0 | EDGAR |
| 2023-10-06 | 4 | ACELYRIN, Inc. (SLRN) | Other (J): 40,763 @ $0 | EDGAR |
| 2023-08-21 | 4 | ACELYRIN, Inc. (SLRN) | Grant/award (A): 254,939 (derivative) @ $0 | EDGAR |
| 2022-06-27 | 4 | Rezolute, Inc. (RZLT) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2022-05-17 | 4 | NEKTAR THERAPEUTICS (NKTR) | Grant/award (A): 28,750 @ $0 · Sale (S): 17,448 @ $3.95 | EDGAR |
| 2022-05-09 | 4/A | Rezolute, Inc. (RZLT) | Purchase (P): 52,631 @ $3.80 | EDGAR |
| 2022-05-06 | 4 | Rezolute, Inc. (RZLT) | Purchase (P): 52,631 @ $3.80 | EDGAR |
| 2022-02-18 | 4 | NEKTAR THERAPEUTICS (NKTR) | Sale (S): 7,579 @ $10.95 | EDGAR |
| 2021-12-20 | 4/A | NEKTAR THERAPEUTICS (NKTR) | Holdings only — no transactions reported | EDGAR |
| 2021-12-20 | 4 | NEKTAR THERAPEUTICS (NKTR) | Grant/award (A): 52,950 @ $0 · Grant/award (A): 94,000 (derivative) @ $0 | EDGAR |
| 2021-11-18 | 4 | NEKTAR THERAPEUTICS (NKTR) | Sale (S): 21,149 @ $13.16 · Sale (S): 3,000 @ $12.69 | EDGAR |
| 2021-11-17 | 4 | NEKTAR THERAPEUTICS (NKTR) | Grant/award (A): 40,150 @ $0 | EDGAR |
| 2021-10-14 | 4 | NEKTAR THERAPEUTICS (NKTR) | Grant/award (A): 71,550 (derivative) @ $0 | EDGAR |
| 2021-08-18 | 4 | NEKTAR THERAPEUTICS (NKTR) | Sale (S): 7,867 @ $13.83 · Sale (S): 3,000 @ $13.56 | EDGAR |
| 2021-07-14 | 4 | Rezolute, Inc. (RZLT) | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2021-05-19 | 4 | NEKTAR THERAPEUTICS (NKTR) | Sale (S): 7,898 @ $18.30 | EDGAR |
| 2021-02-18 | 4 | NEKTAR THERAPEUTICS (NKTR) | Sale (S): 7,977 @ $22.37 | EDGAR |
| 2021-02-04 | 4 | NEKTAR THERAPEUTICS (NKTR) | Option exercise (M): 50,000 @ $8.80 · Sale (S): 41,135 @ $19.97 · Sale (S): 6,932 @ $20.96 · Sale (S): 1,933 @ $21.66 · Option exercise (M): 25,000 @ $8.80 · Option exercise (M): 25,000 @ $8.80 · +7 more | EDGAR |
| 2020-12-22 | 4 | NEKTAR THERAPEUTICS (NKTR) | Grant/award (A): 40,000 @ $0 · Grant/award (A): 71,500 (derivative) @ $0 | EDGAR |
| 2020-11-18 | 4 | NEKTAR THERAPEUTICS (NKTR) | Sale (S): 8,276 @ $16.93 | EDGAR |
| 2020-09-21 | 4 | NEKTAR THERAPEUTICS (NKTR) | Sale (S): 2,000 @ $19.96 | EDGAR |
| 2020-08-19 | 4 | NEKTAR THERAPEUTICS (NKTR) | Sale (S): 6,245 @ $19.67 · Sale (S): 2,000 @ $19.68 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-18 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1394875 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs